CytomX Therapeutics, Inc. (CTMX) Form 8-K — Jun 3, 2026

$CTMXForm 8-KItems 1.01Filed Jun 3, 2026, 4:15 PM ET0001193125-26-255467Original filing

CytomX Therapeutics announced an amendment to its collaboration agreement with Regeneron Pharmaceuticals, allowing for up to eight additional bispecific cancer therapy programs. The amendment extends the program selection period and enables Regeneron to nominate new targets using CytomX’s Probody platform combined with Regeneron’s Veloci-Bi technology. Regeneron immediately nominated the first two of these additional programs, triggering $37 million in target nomination payments to CytomX. The remaining six programs are subject to future nomination options and per-program fees.

Key figures

Deal Value Usd: 4000000000
Programs nominated now: 2
Additional programs allowed: 8
Immediate nomination payments: 37000000

Price after filing

1 day: -1.2%7 days: -9.6%30 days: +18.6%

Close on the filing date to close N calendar days later (from $3.22). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.